GLP-1 receptor agonists — including semaglutide (brand names Ozempic® and Wegovy®) and tirzepatide (Mounjaro®, Zepbound®) — represent one of the most significant advances in obesity medicine in decades. Unlike older weight loss drugs that simply suppress appetite, these medications work through sophisticated hormonal pathways that address both hunger and metabolism in a way that closely mimics natural biology.
How GLP-1 Medications Work
GLP-1 (glucagon-like peptide-1) is a hormone naturally released by your gut after eating. It signals your brain to reduce appetite, slows gastric emptying (keeping you fuller longer), and improves insulin sensitivity. GLP-1 receptor agonist medications amplify this natural signal, creating a sustained state of appetite regulation and improved metabolic function.
Tirzepatide adds a second mechanism — it also activates GIP (glucose-dependent insulinotropic polypeptide) receptors, making it a "dual agonist" with additional metabolic benefits beyond GLP-1 alone. Clinical trials show tirzepatide produces greater average weight loss than semaglutide.
Semaglutide vs. Tirzepatide: Key Differences
- Semaglutide (Wegovy/Ozempic): Single GLP-1 agonist; FDA approved for weight loss (Wegovy) and type 2 diabetes (Ozempic)
- Tirzepatide (Zepbound/Mounjaro): Dual GLP-1/GIP agonist; produces ~20–26% body weight reduction in trials vs. ~15% for semaglutide
- Both: Weekly subcutaneous (under-skin) self-injections; slow dose escalation over months
- Both: Most effective when combined with dietary and lifestyle support
- Side effects: Nausea, constipation, and GI effects are common early on for both; usually resolve as dose increases
Who Is a Good Candidate for GLP-1 Therapy?
Under physician supervision, GLP-1 medications are appropriate for adults who meet certain medical criteria:
- 1BMI ≥ 30 kg/m² (obesity), OR BMI ≥ 27 with a weight-related health condition (type 2 diabetes, hypertension, dyslipidemia, sleep apnea)
- 2No personal or family history of medullary thyroid cancer or MEN2 syndrome
- 3No active pancreatitis or history of pancreatitis
- 4Commitment to concurrent dietary, behavioral, and physical activity changes
- 5Realistic expectations about long-term maintenance (medication is typically continued indefinitely)
The Asira Medical Physician-Supervised Approach
Dr. Grover's weight management program is built around a comprehensive medical evaluation — including metabolic panel, body composition analysis, hormone assessment, and cardiovascular screening. GLP-1 medications are only one component of a program that also includes nutritional coaching, behavioral strategies, and monitoring for side effects and nutritional deficiencies.
Asira Medical: GLP-1 medications are highly effective but work best under physician supervision. Dr. Grover offers comprehensive, personalized medical weight loss programs at Asira Medical. Schedule your evaluation today.
Book a Consultation
